Call for Abstract
3rd European Conference on Pharmacovigilance and Drug Safety, will be organized around the theme ““COVID-19 Challenges for Pharmacovigilance and Drug Safety “”
Euro Pharmacovigilance 2022 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Euro Pharmacovigilance 2022
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Biopharmaceutical science is the study of how biological molecules can be designed, manufactured and used as medicines. The course puts you at the forefront of recent trends in pharmaceutical research, in which increasing numbers of drugs are coming from large biopharmaceutical molecules.
- Track 1-1pharmacokinetics
- Track 1-2Pharmaceutical Sciences
- Track 1-3drug development
- Track 1-4 Clinical Research
- Track 1-5statistical analysis
Clinical analysis comprises exploring deliberate medical treatments, evaluating the relative advantages of good therapies, and beginning optimum treatment combos. Clinical analysis makes an attempt to answer queries like “should a person with glandular carcinoma endure radical ablation or radiation or wait and see?” Statistics play a awfully important role in any run from style, conduct, analysis and reportage in terms of dominant for and minimizing biases, contradictory factors, and mensuration irregular errors. A grasp of applied math strategies is crucial to understanding randomized trial strategies and results.
- Track 2-1clinical trials
- Track 2-2Clinical Research
The drug safety thought has reached plenty of attention during the past period cheers to the very fact it plays a important role in patients’ health. Current laws stress this idea must to be enclosed within the method of latest medications’ support and continued conduct of post-marketing drug evaluations. Benefit–risk assessment ought to be supposed of by all health care professionals when they ought to offer exact medicine to detailed teams of patients. Consequently, additional care ought to slope to some patients, like pregnant girls, youngsters and therefore the aged, meanwhile they're thought of susceptible populations.
- Track 3-1Adverse drug reaction
- Track 3-2pharmacoepidemiology
- Track 3-3pharmacology
A drug-related Problem (DRP) is an occasion or condition regarding drug medical aid that actually or perhaps inhibits with anticipated health results Drug medical aid matters area unit the clinical domain of the pharmaceutical care practician. The aim of individual drug medical aid subjects is to contribution patients reach their goals of medical aid and know the most effective potential results from drug medical aid within the next sections, and to discuss the nomenclature, components, and classes of drug medical aid subjects and their central position to the smear of pharmaceutical care and medicine management services.
- Track 4-1Drug-related problems
- Track 4-2drug therapy
- Track 4-3medical wards
Pharmacovigilance key goal is to carry clear information concerning drug safety and its Risk or compensations of medicine to the patients. Patients are chief finish operators of medication. Patient information leaflet with reference to medication to be providing to the patient to spread the welfares of the medication and to scale back the casual related to them. It's vital for Risk reduction by creating associate early discovery and preventing the development of the adverse effects. Whole info of inadvertent and severe adverse events may well be discovery through the Pharmacovigilance. It couldn't be done through clinical trials that are lead in associate in vivo methodology.
- Track 5-1Drug Safety
- Track 5-2erice declaration
- Track 5-3pharmacovigilance
ER dosage forms are formulated to make the drug available over an extended period after ingestion. This allows a reduction in dosage frequency compared to the drug presented as a conventional dosage form (e.g., an IR dosage form). These products typically provide numerous benefits, including greater effectiveness in the treatment of chronic conditions, reduced side effects, greater convenience, and higher levels of patient compliance due to a simplified dosing schedule. The term controlled release (CR) and extended release are often used interchangeably. A number of design options are available to control or modulate the drug release from a dosage form. Majority of the oral dosage forms fall in the category of matrix, reservoir, osmotic systems, or ion exchange resins. DR dosage forms release the drug at a time other than immediately following oral administration.
- Track 6-1drug delivery system
- Track 6-2 oral infectious diseases
- Track 6-3stimuli-responsive DDS
- Track 6-4oral drug delivery
The Pharmaceutical science is an extortionate scope of logical controls of revelation and advancement of newly developed medications and treatments. Pharmaceutical sciences includes the basic fundamental standards of physical and compound science, designing, organic chemistry, and science to see how to upgrade transference of medications to the body and make an interpretation of this coordinated comprehension into as good as ever treatments against human ailment.
.Drug Discovery and Design
.Drug Discovery and Design
- Track 7-1pharmacovigilance
- Track 7-2Pharmacy
Good pharmacovigilance practices (GVP) are a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU). GVP apply to marketing-authorisation holders, the European Medicines Agency (EMA) and medicines regulatory authorities in EU Member States.
- Track 8-1veterinary pharmacovigilance
- Track 8-2Herbal Cosmetic Nutra
- Track 8-3pharmacovigilance
- Track 8-4egulatory harmonization
The guideline on GVP was a key deliverable of the 2010 pharmacovigilance legislation.
Each chapter and revisions are developed by a team consisting of experts from EMA and from EU Member States.
The guideline on GVP is divided into chapters that fall into two categories:
modules covering major pharmacovigilance processes;
.product- or population-specific considerations.
.Modules covering major pharmacovigilance processes
- Track 9-1risk management
- Track 9-2 Drug
- Track 9-3bioequivalence
- Track 9-4generic drugs
We rapid associate adverse drug reaction as “an noticeably damaging or unfriendly reaction, subsequent from associate interference associated with the service of a healthful product that forecasts hazard from future administration and warrants bar or exact treatment or change of the dose plan, or extraction of the merchandise.” Such responses are presently reportable by use of WHO's Adverse Reaction nomenclature, which is able to ultimately become a set of the International Classification of Diseases.
.An noticeably damaging or unfriendly reaction
.change of the dose plan
.extraction of the merchandise
.warrants bar or exact treatment
.ultimately become a set of the International Classification of Diseases.
- Track 10-1adverse drug event
- Track 10-2Adverse drug reaction
- Track 10-3Pediatrics
- Track 10-4Pediatric safety
- Track 11-1 Clinical evaluation
- Track 11-2Drug risk
- Track 11-3Drugs
Deciding whether a drug is ready for clinical trials (the so-called move from bench to bedside) involves extensive preclinical studies that yield preliminary efficacy, toxicity, pharmacokinetic and safety information. Wide doses of the drug are tested using in vitro (test tube or cell culture) and in vivo (animal) experiments, and it is also possible to perform in silico profiling using computer models of the drug–target interactions.
Much like for clinical trials, there are certain types of trials that have to be done, such as toxicology studies in most cases, and other trials that are specific to the particular study compound or question. Understanding that the goal of preclinical trials is to move into the clinical stage is key and the studies should be designed around that goal. Watch our online seminar on moving from preclinical to clinical trials.
Clinical trial phases:
The entire process of moving a drug from design to clinical trials takes 10 to 12 years on average. Let’s take a closer look at each stage to better understand what goes into early clinical development and preparation for approval of a drug.
- Track 12-1drug development
- Track 12-2phase I trial
- Track 12-3clinical studies
Drug-related problems (DRP) are common in the elderly population, especially in people living with dementia (PwD). DRP are associated with adverse outcomes that could result in increased costs. Objective:The objective of the study was to analyze the association between DRP and healthcare costs in PwD. Methods:The analysis was based on the cross-sectional data of 424 PwD. Compliance, adverse effects, and drug administration of prescribed and over-the-counter drugs taken were assessed. DRP were identified and classified by pharmacists using an adapted German version of “PIE-Doc®”. Healthcare utilization was assessed retrospectively used to calculated costs from a public payer perspective using standardized unit costs.
. potential inadequate medication
- Track 13-1primary health care
- Track 13-2systematic review
- Track 13-3medication review
- Track 13-4pharmaceutical service
A biomaterial is any substance that has been engineered to interact with biological systems for a medical purpose - either a therapeutic (treat, augment, repair or replace a tissue function of the body) or a diagnostic one. Biomaterials conferences can be derived either from nature or synthesized in the laboratory using a variety of chemical approaches utilizing metallic components, polymers, ceramics or composite materials. They are often used and/or adapted for a medical application, and thus comprise whole or part of a living structure or biomedical device which performs, augments, or replaces a natural function. Such functions may be benign, like being used for a heart valve, or may be bioactive with a more interactive functionality such as hydroxy-apatite coated hip implants. Biomaterials 2021 are also used every day in dental applications, surgery, and drug delivery. For example, a construct with impregnated pharmaceutical products can be placed into the body, which permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as a transplant material.
.Cells and proteins
.Biomaterials & therapeutics
.3D printing technologies
.Biomaterials processing & devices
.Ceramics and metals
.Proteins and surfaces
- Track 14-1 drug delivery
- Track 14-2 immune therapy
- Track 14-3polymers
Quality is always an imperative prerequisite when we consider any product. Therefore, drugs must be manufactured to the highest quality levels. End-product testing by itself does not guarantee the quality of the product. Quality assurance techniques must be used to build the quality into the product at every step and not just tested for at the end. In pharmaceutical industry 2019, Process Validation performs this task to build the quality into the product because according to ISO 9000:2000, it had proven to be an important tool for quality management of pharmaceuticals. Validation is one of the important steps in achieving and maintaining the quality of the final product. If each step of production process is validated we can assure that the final product is of the best quality. Validation of the individual steps of the processes is called the process validation. Different dosage forms have different validation protocols. Process Validation is one of the important steps in achieving and maintaining the quality of final product. It gives a higher degree of assurance.
For more information visit: Pharmaceutical Conferences
.Process validation and drug quality
.Approach to process validation
.Statutory and regulatory requirements for process validation
.Types of process validation
.Validation protocol and report
- Track 15-1Analytical method validation
- Track 15-2Process validation
- Track 15-3Cleaning validation